ANI Pharmaceuticals, Inc.
HealthcareNASDAQ:ANIP · NASDAQ Global Market
+$0.03 today
Vol 0.18M · Avg 0.35M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$923.7M of revenue converted into $89.7M of net income for the selected period. Gross margin is 65.4% and net margin is 9.5%, showing how much revenue survives after costs and taxes. EPS is $3.94, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $883.4M +43.8% | $614.4M +26.2% | $486.8M +53.9% | $316.4M +46.4% | $216.1M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $432.7M +72.9% | $250.2M +37.8% | $181.5M +30.8% | $138.8M +37.9% | $100.6M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $450.6M +23.7% | $364.2M +19.3% | $305.3M +71.9% | $177.6M +53.7% | $115.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 51.0% -8.3pp | 59.3% -3.4pp | 62.7% +6.6pp | 56.1% +2.7pp | 53.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $51.7M +15.9% | $44.6M +30.0% | $34.3M +53.6% | $22.3M +96.3% | $11.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $317.7M +27.3% | $249.6M +54.4% | $161.7M +30.4% | $124.0M +47.2% | $84.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $369.4M +1.6% | $363.6M +40.7% | $258.3M +21.3% | $212.9M +37.1% | $155.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $91.4M +35.0% | $67.7M +13.3% | $59.8M +0.2% | $59.7M +26.2% | $47.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | $207.3M +228.4% | $63.1M -40.8% | $106.6M +325.7% | $25.0M +703.6% | $3.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 23.5% +13.2pp | 10.3% -11.6pp | 21.9% +14.0pp | 7.9% +6.5pp | 1.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | $81.2M +13809.2% | $584.0K -98.8% | $47.0M +233.1% | -$35.3M +11.3% | -$39.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 9.2% +9.1pp | 0.1% -9.6pp | 9.6% +20.8pp | -11.2% +7.3pp | -18.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $20.1M +14.0% | $17.6M -34.7% | $26.9M -4.0% | $28.1M +135.3% | $11.9M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $14.6M +163.9% | -$22.8M +15.9% | -$27.1M +1.0% | -$27.4M -68.3% | -$16.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $95.8M +531.3% | -$22.2M -211.8% | $19.9M +131.7% | -$62.7M -11.8% | -$56.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 10.8% +14.5pp | -3.6% -7.7pp | 4.1% +23.9pp | -19.8% +6.1pp | -25.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $17.5M +573.0% | -$3.7M -437.6% | $1.1M +107.4% | -$14.8M -9.8% | -$13.5M | $1.3B | -$1.6B | $745.2M |
| Net Income | $78.3M +522.9% | -$18.5M -198.6% | $18.8M +139.2% | -$47.9M -12.4% | -$42.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 8.9% +11.9pp | -3.0% -6.9pp | 3.9% +19.0pp | -15.1% +4.6pp | -19.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $4 +436.5% | -$1 -209.5% | $1 +131.1% | -$3 +10.3% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $3 +419.2% | -$1 -210.6% | $1 +130.8% | -$3 +10.3% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $20.1M +3.8% | $19.3M +7.3% | $18.0M +10.7% | $16.3M +29.1% | $12.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $21.2M +9.9% | $19.3M +6.2% | $18.2M +11.9% | $16.3M +29.1% | $12.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Hisamitsu Pharmaceutical Co., Inc.
HTSUF
$2.04B
Trulieve Cannabis Corp.
TCNNF
$1.99B
Dermapharm Holding SE
DMPHF
$1.96B
Fagron N.V.
ARSUF
$1.95B
Green Thumb Industries Inc.
GTBIF
$1.85B
Tsumura & Co.
TSMRF
$1.73B
Harrow Health, Inc.
NASDAQ:HROW
$1.40B
CanSino Biologics Inc.
CASBF
$1.08B
Tilray Brands, Inc.
NASDAQ:TLRY
$595.63M
BGM Group Ltd.
NASDAQ:BGM
$75.23M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ANIP generate?
ANI Pharmaceuticals, Inc. (ANIP) reported $883.37M of revenue in fiscal 2025.
Is ANIP profitable?
ANI Pharmaceuticals, Inc. (ANIP) reported $78.34M of net income, with a net margin of 8.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.